Taysha Gene Therapies Financial Results
Taysha Gene Therapies reported third quarter 2026 financial results and provided a corporate update on its TSHA-102 gene therapy program for Rett syndrome. The company completed its BLA-enabling manufacturing campaign and expects to report topline 6-month interim data and receive FDA feedback on its BLA submission pathway in the first half of 2027.
“During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a potential BLA submission for TSHA-102. With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed across all studies, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome.”
Sean P. Nolan, Chairman and Chief Executive Officer of Taysha